Scalar Gauge Management LLC Sells 428,513 Shares of Enfusion, Inc. (NYSE:ENFN)

Scalar Gauge Management LLC decreased its holdings in shares of Enfusion, Inc. (NYSE:ENFN) by 94.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 25,000 shares of the company’s stock after selling 428,513 shares during the period. Enfusion makes up about 0.1% of Scalar Gauge Management LLC’s holdings, making the stock its 27th largest holding. Scalar Gauge Management LLC’s holdings in Enfusion were worth $258,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Centiva Capital LP raised its position in shares of Enfusion by 5.0% during the 3rd quarter. Centiva Capital LP now owns 25,596 shares of the company’s stock valued at $243,000 after buying an additional 1,227 shares in the last quarter. Rhumbline Advisers increased its stake in Enfusion by 3.0% in the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock valued at $643,000 after acquiring an additional 1,796 shares during the last quarter. Azora Capital LP raised its position in Enfusion by 6.8% during the third quarter. Azora Capital LP now owns 29,827 shares of the company’s stock valued at $283,000 after purchasing an additional 1,890 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Enfusion by 3.3% during the fourth quarter. Bank of New York Mellon Corp now owns 126,541 shares of the company’s stock worth $1,303,000 after purchasing an additional 4,032 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Enfusion by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 371,151 shares of the company’s stock worth $3,823,000 after purchasing an additional 5,639 shares in the last quarter. 81.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Enfusion

In related news, insider Bronwen Bastone sold 3,126 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total transaction of $35,573.88. Following the completion of the transaction, the insider now owns 221,875 shares in the company, valued at $2,524,937.50. This represents a 1.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Oleg Movchan sold 2,771 shares of Enfusion stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the sale, the chief executive officer now owns 526,702 shares in the company, valued at approximately $5,335,491.26. This trade represents a 0.52 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 77,346 shares of company stock worth $868,109. 36.44% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Stifel Nicolaus boosted their target price on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler boosted their price objective on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. Finally, William Blair reaffirmed a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th.

Enfusion Price Performance

ENFN opened at $11.11 on Monday. The stock’s 50 day simple moving average is $11.18 and its 200 day simple moving average is $10.21. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of 277.69, a PEG ratio of 1.85 and a beta of 0.95. Enfusion, Inc. has a 1 year low of $7.83 and a 1 year high of $11.80.

Enfusion (NYSE:ENFN) last issued its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The firm had revenue of $52.94 million during the quarter, compared to the consensus estimate of $53.98 million. As a group, sell-side analysts anticipate that Enfusion, Inc. will post 0.06 EPS for the current year.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.